News & Updates

Patients with breast or gastrointestinal (GI) cancer who are being treated with capecitabine monotherapy may benefit from using topical diclofenac gel to prevent or reduce the incidence of hand-foot syndrome (HFS), a common side effect of some chemotherapy drugs, reports a recent study presented at ESMO 2023.

First-line treatment with TST001 (osemitamab) in combination with capecitabine and oxaliplatin (CAPOX) is safe and well tolerated in patients with advanced gastric/gastroesophageal junction (G/GEJ) cancer, according to a study presented at ESMO 2023.

Patients with severe asthma who were dependent on oral corticosteroid (OCS) were able to reduce their use of maintenance OCS after treatment with the monoclonal antibody tezepelumab, according to findings from the interim analysis of the phase IIIb WAYFINDER trial.

In patients treated with drug-eluting stents (DES) for acute coronary syndrome (ACS), stopping aspirin within a month of dual antiplatelet therapy (DAPT) and continuing with ticagrelor alone outdid a 12-month DAPT regimen with ticagrelor and aspirin, findings from the T-PASS trial have shown.